Diego Miralles
Board Member at Artiva Biotherapeutics
San Diego, California
Overview
Work Experience
Board Member
2024 - Current
Advisor
2022 - 2023
CEO-Partner
2020 - 2022
Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Chief Executive Officer
2020 - 2022
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.
Raised $490,000,000.00 from BlackRock, Invus, Flagship Pioneering, T. Rowe Price, Federated Kaufmann Fund, Longevity Vision Fund, Fidelity and CPP Investments.
Chief Executive Officer
2017 - 2020
Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.
Raised $371,504,616.00 from Woodline Partners, Avoro Capital Advisors, Logos Capital, SoftBank Vision Fund, Boxer Capital, Acuta Capital Partners, T. Rowe Price, Surveyor Capital, Nextech Invest and Driehaus Capital Management.
President, Adaptive Therapeutics
2016 - 2017
Adaptive Biotechnologies is the leader in next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system. Adaptive Therapeutics is a new division of Adaptive Biotechnologies focused on the application of the Company’s proprietary technologies to determine the antigen-specificity of T- and B-cell receptors for use in therapies that will directly impact patient outcomes. Adaptive is exploring many potential therapeutic applications including adoptive cell therapy, passive immunization, novel target discovery, and antibody engineering.
Adaptive Biotechnologies translates scale and precision of the adaptive immune system into products to diagnose and treat disease.
Raised $531,850,000.00 from OrbiMed.
Global Head Innovation
2015 - 2016
Over my 7 years in my leading role in Innovation at Johnson and Johnson, I was the founder of JLABS, a best in class corporate incubator in the life sciences and the Innovation Center system.
Head, West Coast Research Center, Janssen
2008 - 2016
Headed large R&D facility focused in pharmaceutical discoveries and early proof of concept clinical development. Site focused in Neuroscience and Pain, Metabolic, Cardiovascular, and Immunology.
Global Head of Innovation Janssen
2013 - 2015
Headed an entrepreneurial team within the Janssen Pharmaceutical Companies of Johnson & Johnson that created integrated care businesses and enabling technologies to transform the healthcare experience, improve outcomes and reduce healthcare costs. Based in the U.S. and Europe. The team created the Care4Today™ (www.care4today.com) master brand to reflect our commitment to transforming healthcare for the consumer.
VP, Scientific Affairs and Strategic Development, Tibotec Therapeutics
2007 - 2008
Was member of the Management Board, oversaw External Innovation, Virology, Drug Safety and Toxicology.
VP, Global Clinical Development, Tibotec Therapeutics
2005 - 2007
Johnson & Johnson is a healthcare provider, expertise in innovative medicine and MedTech for every patient & for everyone.
Senior Director
2000 - 2005
Assistant Professor
1993 - 2005
Duke Health specializes in cancer care, primary care, general pediatrics, ophthalmology, neurology, and cardiology.
Raised $236,193.00 from North Carolina Biotechnology Center and North Carolina Biotechnology Center.
Medical Director
1998 - 2000